[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-329440-105":59,"doc-detail-329440-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","prognostic-value-of-lncrna-cbr3-as1-for-patients-with-cancer-a-meta-analysis","Prognostic value of lncRNA CBR3-AS1 for patients with cancer - A meta-analysis","","This meta-analysis investigates how lncRNA CBR3-AS1 expression relates to prognosis and clinicopathological characteristics in cancer patients. Background studies suggest CBR3-AS1 is overexpressed across multiple cancers and may function as an oncogenic factor. A systematic search in PubMed, Web of Science, Cochrane Library, and EMBASE pooled hazard ratios and odds ratios using 95% confidence intervals to assess survival and tumor features.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-value-of-lncrna-cbr3-as1-for-patients-with-cancer-a-meta-analysis/329440/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-value-of-lncrna-cbr3-as1-for-patients-with-cancer-a-meta-analysis/329440.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of analyzing lncRNA CBR3-AS1 in cancer patients?","Question",{"text":112,"@type":113},"To clarify the relationship between lncRNA CBR3-AS1 expression and patient prognosis as well as clinicopathological features in cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and statistical measures were used in the meta-analysis?",{"text":117,"@type":113},"The study searched PubMed, Web of Science, Cochrane Library, and EMBASE, and used pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals to evaluate outcomes and clinicopathological associations.",{"name":119,"@type":110,"acceptedAnswer":120},"What prognostic effect was found for higher lncRNA CBR3-AS1 expression?",{"text":121,"@type":113},"Overexpression was significantly linked to shorter overall survival, with a pooled hazard ratio of 1.69 (95% CI 1.28–2.21, P \u003C .001).",{"name":123,"@type":110,"acceptedAnswer":124},"How did lncRNA CBR3-AS1 expression relate to tumor characteristics?",{"text":125,"@type":113},"Elevated expression correlated with larger tumor size, lymph node metastasis, distant metastasis, and advanced tumor-node-metastasis stage (III/IV vs I/II), indicating worse clinicopathological outcomes.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},329440,1790466041,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","®  \nSystematic Review and Meta-Analysis   \nPrognostic value of lncRNA CBR3-AS1 for patients with cancer  \nA meta-analysis  \nJun Peng, MMa ,* , Daidong Wang, MMa , Shixue Liu, MMa  \n\n| Abstract\u003Cbr>Background: Several studies have shown that the long noncoding RNA (lncRNA) CBR3-AS1 is overexpressed in various cancers and is playing an oncogene role. This meta-analysis aims to elucidate the relationship between lncRNA CBR3-AS1 expression and the prognosis and clinicopathological features of cancer patients.\u003Cbr>Methods: A comprehensive and systematic search was conducted in PubMed, Web of Science, Cochrane Library, and EMBASE database. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were employed to evaluate the association between lncRNA CBR3-AS1 expression and clinical outcomes and clinicopathological features in cancer patients. Results: This meta-analysis finally enrolled 9 studies comprising 800 cancer patients. The combined results indicated that lncRNA CBR3-AS1 overexpression was significantly associated with shorter overall survival (pooled hazard ratios = 1.69, 95% CI 1.28–2.21, P \u003C .001) . Furthermore, elevated lncRNA CBR3-AS1 expression was closely correlated with larger tumor size (large vs small OR = 2. 17, 95% CI: 1.50–3. 14, P \u003C .0001), lymph node metastasis (yes vs no OR = 2.75, 95% CI: 1.67–4.51, P \u003C .0001), distant metastasis (yes vs no OR = 3.08, 95% CI: 1.82–5.23, P \u003C .0001), and advanced tumour, node, metastasis stage (III/IV vs I/II OR = 2.82, 95% CI: 1.68–4.75, P \u003C .0001) .\u003Cbr>Conclusion: Upregulated expression of lncRNA CBR3-AS1 showed significant association with unfavorable survival and indicated worse clinicopathological outcomes in multiple kinds of human cancer, and therefore might serve as a promising prognosis biomarker and therapeutic target for cancers.\u003Cbr>Abbreviations: CBR3 = carbonyl reductase 3, ceRNA = competing endogenous RNA, CI = confidence interval, HRs = hazard ratios, lncRNA = long noncoding RNA, ORs = odds ratios, OS = overall survival, PlncRNA-1 = prostate cancer regulatory long noncoding RNA 1. |\n| --- |\n| Keywords: cancer, lncRNA CBR3-AS1 , meta-analysis, prognosis |\n\n1. Introduction  \nCancer remains the leading cause of death worldwide, posing a major public health challenge.[1,2] Even though significant advances have been made in diagnosis and therapeutic techniques in recent years, the prognosis for many patients with advanced cancer remains poor.[3] The lack of effective biomarkers as therapeutic targets and prognostic indicators is considered to be a primary reason for this predicament.[4] Consequently, researchers have focused on identifying optimal biomarkers for human cancers.[5]  \nLong noncoding RNAs (lncRNAs), defined as RNA molecules longer than 200 nucleotides, is an important member of the noncoding RNA family.[6] Although most lncRNAs cannot encode proteins, they are actively involved in most cellular and physiological processes by acting as posttranscriptional regulators,  \nenhancers, splicing regulators, and chromosomal modifiers.[7] Numerous studies have demonstrated that lncRNAs play an important role in the pathogenesis and prognosis of malignant tumors, as well as in diverse biological processes such as tumor cell proliferation, invasion, and metastasis.[8] Consequently, lncRNAs hold promise as biomarkers and therapeutic targets for cancer.[9]  \nLncRNA CBR3-AS1, also known as PlncRNA-1 or prostate cancer regulatory long noncoding RNA 1), is located in the antisense region of carbonyl reductase 3 (CBR3) . It was initially identified as being overexpressed in prostate cancer tissues and cell lines compared to corresponding normal controls. [10] In recent years, elevated expression of lncRNA CBR3-AS1 has been observed in various cancer types, and its overexpression has been associated with prognostic significance. [11–19]  \nThe authors have no conflicts of interest to disclose.  \nAll data generated or analyzed during this study ar","cbCaidJeue7LX0AN","https://ap.wps.com/l/cbCaidJeue7LX0AN","pdf",1282844,"English","# Abstract\n# Introduction\n# Methods\n## Publication search","[{\"question\":\"What is the purpose of analyzing lncRNA CBR3-AS1 in cancer patients?\",\"answer\":\"To clarify the relationship between lncRNA CBR3-AS1 expression and patient prognosis as well as clinicopathological features in cancer.\"},{\"question\":\"Which databases and statistical measures were used in the meta-analysis?\",\"answer\":\"The study searched PubMed, Web of Science, Cochrane Library, and EMBASE, and used pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals to evaluate outcomes and clinicopathological associations.\"},{\"question\":\"What prognostic effect was found for higher lncRNA CBR3-AS1 expression?\",\"answer\":\"Overexpression was significantly linked to shorter overall survival, with a pooled hazard ratio of 1.69 (95% CI 1.28–2.21, P \\u003c .001).\"},{\"question\":\"How did lncRNA CBR3-AS1 expression relate to tumor characteristics?\",\"answer\":\"Elevated expression correlated with larger tumor size, lymph node metastasis, distant metastasis, and advanced tumor-node-metastasis stage (III/IV vs I/II), indicating worse clinicopathological outcomes.\"}]","Prognostic value of lncRNA CBR3-AS1 for patients with cancer - A meta-analysis | PDF",1789984125,15]